MedTrace Logo

Rood's Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients

NCT05882396 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-31

No results posted yet for this study

Summary

Oxaliplatin-induced chronic peripheral neuropathy is of major concern to oncologists and patients as it has been shown to affect patients' health-related quality of life. Although a number of interventions have been implicated, none of them can be recommended for clinical use. This therapeutic failure reflects a poor understanding of the real mechanism of oxaliplatin-induced neuropathy. However, oxidative stress is identified to be one of the main biomolecular dysfunctions in this neuropathy. Rood's approach is a neurophysiological approach that is based on reflexes of the central nervous system in which the sensory stimulation provides desired muscular response and was specially designed for patients with motor control problems. It was developed by Margeret Rood in 1940. According to Rood, sensory stimulation can activate or deactivate the receptor by facilitation or inhibition, which makes it possible to get the desired muscular response.

Conditions

Interventions

OTHER

Rood's approach

Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.

OTHER

Traditional physical therapy program

Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Shaimaa MA El Sayeh, PhD · Lecturer at Faculty of Physical Therapy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-12-28
Completion
2024-01-11

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05882396 on ClinicalTrials.gov